Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announced today that it has been awarded a cash grant totaling $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

9 Nov 2010

TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

In advance of the 41st Union World Conference, the Global Alliance for TB Drug Development (TB Alliance) today announced the launch of the first clinical trial to test a novel tuberculosis regimen in a new development paradigm designed to speed new treatments to patients. This novel three-drug combination shows promise to treat both drug-sensitive (DS-TB) and multidrug-resistant TB (MDR-TB), and alter the course of the TB pandemic by shortening and simplifying treatment worldwide.

8 Nov 2010

Study suggests bacterial products contribute to autoimmune diseases

Researchers are using 21st century technologies to investigate the century old hypothesis that certain autoimmune diseases, including rheumatoid arthritis, are caused by bacteria living in the human body and will present their initial data this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

AHRQ grants $34 million to prevent healthcare-associated infections

HHS' Agency for Healthcare Research and Quality today announced the award of $34 million for projects focused on preventing one of the top 10 leading causes of death in the United States - healthcare-associated infections (HAIs). This new funding will help improve the quality of care delivered to patients and expand the fight against HAIs in hospitals, ambulatory care settings, end-stage renal disease facilities and long-term care facilities.

8 Nov 2010

EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT(R) (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

4 Nov 2010

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has been awarded a cash grant under the Qualifying Therapeutic Discovery Project which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

Nanotherapeutics receives contract from DOD to support clinical trial for treating dehisced surgical wounds

Nanotherapeutics, Inc. announced that it has been awarded a contract by the U.S. Department of Defense to support a clinical trial for treating dehisced surgical wounds with the Company's NanoDOX Hydrogel, a topical doxycycline hydrogel for chronic wounds.

4 Nov 2010

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae.

4 Nov 2010

MicroPhage receives $977,916 QTDP grant for development of MRSA/MSSA Blood Culture Test

MicroPhage, Inc. announced today that it has received two Qualifying Therapeutic Discovery Project (QTDP) grants totaling $977,916 from the IRS. The grants, awarded as part of the Affordable Care Act, apply to small-company R&D expenditures that reduce the cost and increase the quality of healthcare in the U.S. The grants will be applied to the development of MicroPhage's first product, the MRSA/MSSA Blood Culture Test, currently under review at the FDA.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

3 Nov 2010

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Immune Network Ltd. a company in the business of discovery and development of immune-based therapies, today announced that patient enrollment will be completed next week for the company's future partner Immunitor's Phase 2b imm01 trial of V5 immunotherapy in 120 patients with tuberculosis.

3 Nov 2010

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with The Walter Reed Army Institute of Research.

2 Nov 2010

Optimer third quarter net loss increases to $11.8 million

Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Optimer reported a net loss for the third quarter of 2010 of $11.8 million, or $0.30 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share. The increase in net loss was primarily due to an increase in research and development and marketing expenses.

2 Nov 2010

Short courses of antibiotics have long-term impact on microbial flora of human gut

Short courses of antibiotics can leave normal gut bacteria harbouring antibiotic resistance genes for up to two years after treatment, say scientists writing in the latest issue of Microbiology, published on 3 November.

1 Nov 2010

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

FDA new approvals, antibiotic and neurological drugs

Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.

31 Oct 2010

Surrogates preference increases for value-laden decisions in ICUs: Report

The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.

30 Oct 2010

New findings on protein factories could unravel cell complexities, lead to new antibiotics and disease treatments

A team from The Scripps Research Institute has revealed the first-ever pictures of the formation of cells' "protein factories." In addition to being a major technical feat on its own, the work could open new pathways for development of antibiotics and treatments for diseases tied to errors in ribosome formation. In addition, the techniques developed in the study can now be applied to other complex challenges in the understanding of cellular processes.

30 Oct 2010

Teflaro receives FDA approval for treatment of bacterial infections

The U.S. Food and Drug Administration today approved Teflaro (ceftaroline fosamil), an injectable antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

Antibiotic News and Research

Further Reading

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

TB Alliance launches three-drug combination trial for drug-sensitive and multidrug-resistant TB

Study suggests bacterial products contribute to autoimmune diseases

AHRQ grants $34 million to prevent healthcare-associated infections

EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

Advanced Life Sciences awarded $244,479.25 grant under Qualifying Therapeutic Discovery Project

Nanotherapeutics receives contract from DOD to support clinical trial for treating dehisced surgical wounds

Cempra to present information on solithromycin antimalarial agent at Atlanta Annual Meeting

MicroPhage receives $977,916 QTDP grant for development of MRSA/MSSA Blood Culture Test

PolyMedix receives $488,958 grants under QTDP program

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

Immune Network to complete patient enrollment in Phase 2b imm01 trial for tuberculosis

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Optimer third quarter net loss increases to $11.8 million

Short courses of antibiotics have long-term impact on microbial flora of human gut

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

FDA new approvals, antibiotic and neurological drugs

Surrogates preference increases for value-laden decisions in ICUs: Report

New findings on protein factories could unravel cell complexities, lead to new antibiotics and disease treatments

Teflaro receives FDA approval for treatment of bacterial infections

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News